BDSI earnings call for the period ending December 31, 2018.
News & Analysis: BioDelivery Sciences International
Will Biodelivery Sciences have any more success commercializing Belbuca?
BioDelivery Sciences' shares push higher on the news that the FDA approved the chronic pain medicine Belbuca.
BioDelivery Sciences International, Inc. shares are dropping after the company reported that it's borrowed $20.7 million.
A key trial failure is sending BioDelivery Sciences International, Inc.'s shares tumbling.
Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
BioDelivery Sciences shares soar after delivering positive top-line phase 3 data from a key pipeline product. Find out what this means for BioDelivery and investors.
Merck, Idenix, Achillion, and BioDelivery Sciences could all make big moves this Monday morning.
Friday's health-care winners and losers.
Two positive clinical results, a symbiotic asset deal, and a rumored takeover target are this week's top stories in Part 2 of "This Week in Biotech."